[go: up one dir, main page]

MX2016008272A - Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona. - Google Patents

Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona.

Info

Publication number
MX2016008272A
MX2016008272A MX2016008272A MX2016008272A MX2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A MX 2016008272 A MX2016008272 A MX 2016008272A
Authority
MX
Mexico
Prior art keywords
hsdd
trazodone
bupropion
methods
sexual desire
Prior art date
Application number
MX2016008272A
Other languages
English (en)
Inventor
E Pyke Robert
Clayton Anita
Taylor Segraves Robert
Derogatis Leonard
Katz Molly
Meston Cindy
G Sitchon Nicholas
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016008272(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of MX2016008272A publication Critical patent/MX2016008272A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos de tratamiento de mujeres para el Trastorno del Deseo Sexual Hipoactivo (HSDD) con tratamientos diarios orales de combinaciones de bajas dosis y altas dosis de trazodona y bupropión.
MX2016008272A 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona. MX2016008272A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
MX2016008272A true MX2016008272A (es) 2017-12-18

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008272A MX2016008272A (es) 2016-06-17 2016-06-20 Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona.

Country Status (9)

Country Link
KR (1) KR20170142797A (es)
AR (2) AR105047A1 (es)
AU (1) AU2016204151A1 (es)
CA (1) CA2933921A1 (es)
CL (1) CL2016001597A1 (es)
MX (1) MX2016008272A (es)
PE (1) PE20180023A1 (es)
UY (1) UY36742A (es)
WO (1) WO2017218018A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
RU2008135326A (ru) * 2006-03-24 2010-04-27 Вайет (Us) Терапевтические композиции для лечения депрессии
US9517254B2 (en) * 2012-08-06 2016-12-13 S1 Biopharma, Inc. Treatment regimens

Also Published As

Publication number Publication date
UY36742A (es) 2016-12-30
PE20180023A1 (es) 2018-01-09
AR105047A1 (es) 2017-08-30
WO2017218018A1 (en) 2017-12-21
CA2933921A1 (en) 2017-12-17
KR20170142797A (ko) 2017-12-28
CL2016001597A1 (es) 2017-10-06
AU2016204151A1 (en) 2018-01-18
AR105087A1 (es) 2017-09-06

Similar Documents

Publication Publication Date Title
PH12020551427A1 (en) Epinephrine spray formulations
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
EA201790737A1 (ru) Комбинированная терапия
MX2017010150A (es) Bacterias probioticas recombinantes.
EA201890411A1 (ru) Терапевтически активные соединения и способы их применения
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
GEP20217317B (en) Combination therapy for the treatment of cancer
SA519410324B1 (ar) صياغات رش إيبينيفرين
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
NZ723884A (en) Methods of treating alzheimer’s disease
EP4353319A3 (en) Methods of adoptive cell therapy
EA201692284A1 (ru) Ниацинамид для стимуляции продуцирования антимикробных пептидов
PH12020550023A1 (en) Compositions for treating stress-related disorders
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
GEP20186939B (en) Medical treatments based on anamorelin
MX2017000306A (es) Metodos para tratar hipotension.
MX382044B (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés.
EA201792560A1 (ru) Наночастицы для применения в качестве терапевтической вакцины
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2019004804A (es) Tratamiento para el prurigo nodula.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
MY197942A (en) Adjuvant therapy for use in prostate cancer treatment
MX2016008272A (es) Metodos para el tratamiento de mujeres con trastornos de deseo sexual hipoactivo (hsdd) con el tratamiento de combinacion bupropion y trazodona.